Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma
Acta Neurol Scand 2006: 113: 322–326.
© 2006 The Authors Journal compilation © 2006 Blackwell Munksgaard. Objectives –
The arylamine N-acetyltransferase (NAT2) is a polymorphic enzyme involved in deactivation and activation of carcinogens through N- and O-acetylation. We investigated the association between the genetic NAT2 polymorphism and brain tumors by analysis of genomic DNA from 71 brain tumor patients and 258 healthy controls. Materials and methods –
Seven single nucleotide polymorphisms of the NAT2 gene were studied by using allele-specific polymerase chain reaction amplification. Results –
Ten different NAT2 allelic variants were identified in both patient and control groups. A higher number of individuals carrying functional NAT2 genes, and therefore with a rapid acetylation phenotype, was found in brain tumor patients vs healthy volunteers (OR 1.79, 95% CI 1.05–3.05; P < 0.05). This is observed either for patients suffering from meningioma or astrocytoma, and this is due to an increase of the wild-type NAT2*4 allelic variant frequency (OR 1.48, 95% CI 0.99–2.19), and a reduction of the commonest defective allelic variant NAT2*5B in the brain tumor patients, compared with healthy subjects (OR 0.54, 95% CI 0.37–0.80). Conclusions –
This observation indicates that NAT2 could be considered as a low-penetrance gene for brain tumors, and that individuals carrying rapid acetylation alleles are at increased risk of developing brain tumors.
Document Type: Research Article
Affiliations: 1: Department of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain 2: Service of Neurology, University Hospital Doce de Octubre, Madrid, Spain 3: Department of Medicine-Neurology, University Hospital Principe de Asturias, Madrid, Spain 4: Department of Biochemistry & Molecular Biology, School of Sciences, University of Extremadura, Badajoz, Spain
Publication date: 2006-05-01